PURPOSE: A bisphosphonate drug for oral administration is provided to enhance bioavailabilitiy of bisphosphonate, to ensure excellent safety, and to treat osteoporosis with improve drug compliance. CONSTITUTION: A bisphosphonate drug for oral administration contains bisphosphonate and inositol hexakisphosphate. The bisphosphonate is alendronate, risedronate, ibandronate, zoledronate, pamidronate, clodronate, tiludronate, cimadronate, or minodronate. A delayed release device is an enteric drug de...

Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein. The compounds are bisphosphonates selected from the group consisting of alendronate cimadronate clodronate tiludronate etridronate ibandronate risedronate piridronate pamidronate zolendronate optionally in combination with a histamine ...

The use of compounds described as bisphosphonates selected from the group consisting of alendronate etidronate (1-hydroxy-ethidene-bisphosphonic acid) pamidronate (3-amino-1-hydroxypropyildiene-11-diphosphanate) risedronate (2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonic acid) clodronate (dichloromethylene-bisphosphonic acid) tiludronate (chloro-4-phenylthiomethylidene-bisphosphonic acid) ibandronic acid (1-hydroxy-3-(methylpentylamino)-propylidene-bisphosphonic acid and pharmaceutically acce...

Disodium tiludronate tetrahydrate is provided for use in pharmaceutical compositions for oral administration in the form of a tablet effervescent composition capsule and the like.

Disodium tiludronate tetrahydrate is provided for use in pharmaceutical compositions for oral administration in the form of a tablet effervescent composition capsule and the like.